© Reuters.
CANTANHEDE, Portugal – Tilray (TSX:) (NASDAQ:) Brands, Inc. (NASDAQ:TLRY; :TLRY), a global leader in the cannabis industry, has achieved a significant milestone in Portugal with the approval of its first medical cannabis extract, Tilray Oral Solution THC 5 CBD 20. This development marks a notable advancement in the availability of medical cannabis products for patients in Portugal.
The approval, granted on March 11, 2024, allows Tilray Medical to provide a new form of therapy to Portuguese patients with certain medical conditions. The Tilray Oral Solution THC 5 CBD 20 is the first medical cannabis extract to be sanctioned in the country, expanding the company’s existing portfolio of EU-GMP certified medicinal cannabis products.
Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, expressed the company’s commitment to medical cannabis research and patient accessibility. “
This is a…
